Global registry for people with HIV who failed newer integrase inhibitors
Part of Infections clinical trials.
This trial is a registry for people with HIV whose virus is no longer fully controlled by certain newer medications (integrase inhibitors). It aims to collect data to better understand why these treatments stop working and how to improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV-1 and have been on HIV medications for at least 6 months.
- Your virus was not controlled (viral load above 50 copies/mL twice, or above 200 copies/mL once) while on a medication called a second-generation integrase inhibitor.
- Your doctor knows the details (start and stop dates, doses) of your current and past integrase inhibitor treatments.
- A test showing your virus's genetics is available, or you can provide a blood sample taken when the treatment stopped working.
- You have not skipped your HIV medications for 2 weeks or more just before the viral load test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for markers in the blood that help some people with HIV stay virus-free without medication for a long time. If you have controlled your HIV without drugs for at least 6 months, or are interested in pausing your medication to see if you can control the virus, this study may help guide future treatments.
This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This study looks at how well newer HIV medicines work in people starting treatment for the first time in Eastern Europe and Russia. It also checks for drug resistance to find better treatment strategies.
This study follows people with a very recent HIV infection and collects blood and other samples to learn more about the infection soon after it starts. It may help researchers better understand early HIV and improve future treatments.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.